

Dean D Metcalfe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6119399/publications.pdf>

Version: 2024-02-01

169
papers

18,516
citations

13332

70
h-index

14012

133
g-index

170
all docs

170
docs citations

170
times ranked

12287
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | IgE, mast cells, basophils, and eosinophils. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, S73-S80. | 1.5 | 1,065 |
| 2 | Diagnostic criteria and classification of mastocytosis: a consensus proposal. <i>Leukemia Research</i> , 2001, 25, 603-625. | 0.4 | 1,020 |
| 3 | Tryptase Levels as an Indicator of Mast-Cell Activation in Systemic Anaphylaxis and Mastocytosis. <i>New England Journal of Medicine</i> , 1987, 316, 1622-1626. | 13.9 | 737 |
| 4 | Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. <i>Blood</i> , 2017, 129, 1420-1427. | 0.6 | 520 |
| 5 | Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal. <i>International Archives of Allergy and Immunology</i> , 2012, 157, 215-225. | 0.9 | 513 |
| 6 | Mast cells and mastocytosis. <i>Blood</i> , 2008, 112, 946-956. | 0.6 | 481 |
| 7 | Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of Fc ϵ 1RI or Fc ϵ 3RI. <i>Leukemia Research</i> , 2003, 27, 677-682. | 0.4 | 473 |
| 8 | The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. <i>Blood</i> , 2002, 99, 1741-1744. | 0.6 | 416 |
| 9 | Cold Urticaria, Immunodeficiency, and Autoimmunity Related to <i>PLCG2</i> Deletions. <i>New England Journal of Medicine</i> , 2012, 366, 330-338. | 13.9 | 391 |
| 10 | Anaphylaxis – a practice parameter update 2015. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 115, 341-384. | 0.5 | 381 |
| 11 | Assessment of the allergenic potential of foods derived from genetically engineered crop plants*. <i>Critical Reviews in Food Science and Nutrition</i> , 1996, 36, 165-186. | 5.4 | 374 |
| 12 | Demonstration That Human Mast Cells Arise From a Progenitor Cell Population That Is CD34+, c-kit+, and Expresses Aminopeptidase N (CD13). <i>Blood</i> , 1999, 94, 2333-2342. | 0.6 | 359 |
| 13 | Factors affecting the determination of threshold doses for allergenic foods: How much is too much?. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 24-30. | 1.5 | 348 |
| 14 | Mast cells in innate immunity. <i>Immunological Reviews</i> , 2000, 173, 131-140. | 2.8 | 338 |
| 15 | A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. <i>Blood</i> , 2004, 103, 3222-3225. | 0.6 | 336 |
| 16 | Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 174-182. | 1.5 | 314 |
| 17 | Classification and Diagnosis of Mastocytosis: Current Status. <i>Journal of Investigative Dermatology</i> , 1991, 96, S2-S4. | 0.3 | 307 |
| 18 | Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 35-45. | 1.5 | 289 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. <i>Nature Genetics</i> , 2016, 48, 1564-1569. | 9.4 | 279 |
| 20 | Mast cell activation syndrome: Proposed diagnostic criteria. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 1099-1104.e4. | 1.5 | 266 |
| 21 | Mechanisms of mast cell signaling in anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 639-646. | 1.5 | 240 |
| 22 | Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. <i>Leukemia Research</i> , 2003, 27, 635-641. | 0.4 | 217 |
| 23 | Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. <i>Experimental Hematology</i> , 2003, 31, 686-692. | 0.2 | 213 |
| 24 | Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017, 77, 1261-1270. | 0.4 | 210 |
| 25 | Human mast cells express functional TrkA and are a source of nerve growth factor. <i>European Journal of Immunology</i> , 1997, 27, 2295-2301. | 1.6 | 209 |
| 26 | Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with α - <i>id</i> anaphylaxis. <i>Blood</i> , 2007, 110, 2331-2333. | 0.6 | 208 |
| 27 | Diagnosis and treatment of systemic mastocytosis: state of the art. <i>British Journal of Haematology</i> , 2003, 122, 695-717. | 1.2 | 187 |
| 28 | Mastocytosis: Pathology, genetics, and current options for therapy. <i>Leukemia and Lymphoma</i> , 2005, 46, 35-48. | 0.6 | 180 |
| 29 | Expression of a Functional High-Affinity IgG Receptor, Fc γ RI, on Human Mast Cells: Up-Regulation by IFN- γ . <i>Journal of Immunology</i> , 2000, 164, 4332-4339. | 0.4 | 176 |
| 30 | Mast cells signal their importance in health and disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 381-393. | 1.5 | 169 |
| 31 | Human mast cells are capable of serotonin synthesis and release. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 498-499. | 1.5 | 163 |
| 32 | Impulse oscillometry in the evaluation of diseases of the airways in children. <i>Annals of Allergy, Asthma and Immunology</i> , 2011, 106, 191-199. | 0.5 | 159 |
| 33 | Understanding the mechanisms of anaphylaxis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2008, 8, 310-315. | 1.1 | 158 |
| 34 | Vibratory Urticaria Associated with a Missense Variant in <i>ADGRE2</i> . <i>New England Journal of Medicine</i> , 2016, 374, 656-663. | 13.9 | 157 |
| 35 | Hematologic manifestations of systemic mast cell disease: A prospective study of laboratory and morphologic features and their relation to prognosis. <i>American Journal of Medicine</i> , 1991, 91, 612-624. | 0.6 | 156 |
| 36 | Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1125-1133.e1. | 2.0 | 150 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. <i>Blood</i> , 2004, 103, 1078-1084. | 0.6 | 147 |
| 38 | Kit and Fc β RI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. <i>Blood</i> , 2004, 104, 2410-2417. | 0.6 | 144 |
| 39 | Isolation and Characterization of Heparin from Human Lung. <i>Journal of Clinical Investigation</i> , 1979, 64, 1537-1543. | 3.9 | 142 |
| 40 | Gastrointestinal Dysfunction in Systemic Mastocytosis. <i>Gastroenterology</i> , 1988, 95, 657-667. | 0.6 | 141 |
| 41 | Heritable risk for severe anaphylaxis associated with increased $\hat{\pm}$ -tryptase $\hat{\epsilon}$ encoding germline copy number at TPSAB1. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 622-632. | 1.5 | 137 |
| 42 | Mast cell numbers in rheumatoid synovial tissues. <i>Arthritis and Rheumatism</i> , 1987, 30, 130-137. | 6.7 | 133 |
| 43 | Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. <i>HemaSphere</i> , 2021, 5, e646. | 1.2 | 128 |
| 44 | International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013, 121, 2393-2401. | 0.6 | 122 |
| 45 | The biology of Kit in disease and the application of pharmacogenetics. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 13-19. | 1.5 | 120 |
| 46 | NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc β RI aggregation. <i>Blood</i> , 2004, 104, 207-214. | 0.6 | 117 |
| 47 | Frequency and characterization of antigen-specific IL-4 $\hat{\epsilon}$ and IL-13 $\hat{\epsilon}$ producing basophils and T cells in peripheral blood of healthy and asthmatic subjects. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 104, 811-819. | 1.5 | 112 |
| 48 | Activation and Function of the mTORC1 Pathway in Mast Cells. <i>Journal of Immunology</i> , 2008, 180, 4586-4595. | 0.4 | 112 |
| 49 | Activation of human mast cells by aggregated IgG through Fc β RI: additive effects of C3a. <i>Clinical Immunology</i> , 2004, 110, 172-180. | 1.4 | 109 |
| 50 | Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: Relationship to symptomatology, tryptase levels, and bone marrow pathology. <i>Journal of the American Academy of Dermatology</i> , 2003, 48, 508-516. | 0.6 | 108 |
| 51 | Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , 2020, 10, 10743-10768. | 4.6 | 107 |
| 52 | Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. <i>Immunology</i> , 2003, 108, 89-97. | 2.0 | 105 |
| 53 | KIT D816V $\hat{\epsilon}$ associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFR $\hat{\alpha}$ -associated chronic eosinophilic leukemia are distinct entities. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 680-687. | 1.5 | 105 |
| 54 | A Comparison of Mediators Released or Generated by IFN- $\hat{\beta}$ -Treated Human Mast Cells Following Aggregation of Fc β RI or Fc β RI. <i>Journal of Immunology</i> , 2001, 166, 4705-4712. | 0.4 | 101 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | The Phospholipase C β 1-dependent Pathway of Fc ϵ RI-mediated Mast Cell Activation Is Regulated Independently of Phosphatidylinositol 3-Kinase. <i>Journal of Biological Chemistry</i> , 2003, 278, 48474-48484. | 1.6 | 100 |
| 56 | Rodent and Human Mast Cells Produce Functionally Significant Intracellular Reactive Oxygen Species but Not Nitric Oxide. <i>Journal of Biological Chemistry</i> , 2004, 279, 48751-48759. | 1.6 | 95 |
| 57 | Mast Cell Migratory Response to Interleukin-8 Is Mediated Through Interaction With Chemokine Receptor CXCR2/Interleukin-8RB. <i>Blood</i> , 1999, 93, 2791-2797. | 0.6 | 93 |
| 58 | Btk Plays a Crucial Role in the Amplification of Fc ϵ RI-mediated Mast Cell Activation by Kit. <i>Journal of Biological Chemistry</i> , 2005, 280, 40261-40270. | 1.6 | 93 |
| 59 | Silica-Directed Mast Cell Activation Is Enhanced by Scavenger Receptors. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2007, 36, 43-52. | 1.4 | 92 |
| 60 | Stem Cell Factor Programs the Mast Cell Activation Phenotype. <i>Journal of Immunology</i> , 2012, 188, 5428-5437. | 0.4 | 90 |
| 61 | Human tissue mast cells are an inducible reservoir of persistent HIV infection. <i>Blood</i> , 2007, 109, 5293-5300. | 0.6 | 87 |
| 62 | Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. <i>International Archives of Allergy and Immunology</i> , 2019, 180, 44-51. | 0.9 | 87 |
| 63 | Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. <i>Haematologica</i> , 2011, 96, 459-463. | 1.7 | 86 |
| 64 | IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1863-1871.e6. | 1.5 | 86 |
| 65 | Impact of naturally forming human β -tryptase heterotetramers in the pathogenesis of hereditary β -tryptasemia. <i>Journal of Experimental Medicine</i> , 2019, 216, 2348-2361. | 4.2 | 85 |
| 66 | Treatment of Three Patients with Systemic Mastocytosis with Interferon Alpha-2b. <i>Leukemia and Lymphoma</i> , 1996, 22, 501-508. | 0.6 | 83 |
| 67 | Functional Deregulation of KIT. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 219-237. | 0.7 | 81 |
| 68 | Btk-dependent Rac activation and actin rearrangement following Fc ϵ RI aggregation promotes enhanced chemotactic responses of mast cells. <i>Journal of Cell Science</i> , 2010, 123, 2576-2585. | 1.2 | 78 |
| 69 | Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356. | 2.0 | 76 |
| 70 | Analysis of plasma histamine levels in patients with mast cell disorders. <i>American Journal of Medicine</i> , 1989, 87, 649-654. | 0.6 | 73 |
| 71 | Activated mast cells synthesize and release soluble ST2 α decoy receptor for IL β 3. <i>European Journal of Immunology</i> , 2015, 45, 3034-3044. | 1.6 | 72 |
| 72 | A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 180-188.e3. | 1.5 | 70 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | The ingenious mast cell: Contemporary insights into mast cell behavior and function. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 83-99. | 2.7 | 69 |
| 74 | The Phosphoinositide 3-Kinase-Dependent Activation of Btk Is Required for Optimal Eicosanoid Production and Generation of Reactive Oxygen Species in Antigen-Stimulated Mast Cells. <i>Journal of Immunology</i> , 2008, 181, 7706-7712. | 0.4 | 66 |
| 75 | Kit- and Fc ϵ RI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL/LAB/LAT2 allows flexibility in its scaffolding function in mast cells. <i>Cellular Signalling</i> , 2008, 20, 195-205. | 1.7 | 64 |
| 76 | Comparison of Fc μ RI- and Fc γ RI-mediated degranulation and TNF- α synthesis in human mast cells: selective utilization of phosphatidylinositol-3-kinase for Fc γ RI-induced degranulation. <i>European Journal of Immunology</i> , 2003, 33, 1450-1459. | 1.6 | 56 |
| 77 | Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9030. | 1.8 | 56 |
| 78 | Synergistic activation of phospholipases C β and C δ : A novel mechanism for PI3K-independent enhancement of Fc μ RI-induced mast cell mediator release. <i>Cellular Signalling</i> , 2008, 20, 625-636. | 1.7 | 55 |
| 79 | Hematopathology of the Bone Marrow in Pediatric Cutaneous Mastocytosis: A Study of 17 Patients. <i>American Journal of Clinical Pathology</i> , 1989, 91, 558-562. | 0.4 | 54 |
| 80 | Immune mechanisms in food allergy. <i>Clinical and Experimental Allergy</i> , 1991, 21, 321-324. | 1.4 | 54 |
| 81 | Food allergens. <i>Clinical Reviews in Allergy</i> , 1985, 3, 331-349. | 1.0 | 53 |
| 82 | Assessing anaphylactic risk? Consider mast cell clonality. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 687-688. | 1.5 | 53 |
| 83 | Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: Correlation with dermal mast-cell numbers and mast-cell tryptase. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 82-88. | 1.5 | 52 |
| 84 | Association of the Q576R polymorphism in the interleukin-4 receptor β chain with indolent mastocytosis limited to the skin. <i>Blood</i> , 2001, 98, 880-882. | 0.6 | 51 |
| 85 | Determination of protein phosphorylation in Fc μ RI-activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions. <i>Journal of Immunological Methods</i> , 2002, 268, 239-243. | 0.6 | 51 |
| 86 | Mastocytosis. <i>Chemical Immunology and Allergy</i> , 2010, 95, 110-124. | 1.7 | 50 |
| 87 | Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A \hat{A} Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 880-893. | 1.5 | 50 |
| 88 | Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2227-2237.e10. | 1.5 | 50 |
| 89 | Pathogenesis and Pathology of Mastocytosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 487-514. | 9.6 | 49 |
| 90 | mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. <i>Blood</i> , 2011, 118, 6803-6813. | 0.6 | 48 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | CD72 Negatively Regulates KIT-Mediated Responses in Human Mast Cells. <i>Journal of Immunology</i> , 2010, 184, 2468-2475. | 0.4 | 47 |
| 92 | Effects of Gamma Radiation on Fc μ RI and TLR-Mediated Mast Cell Activation. <i>Journal of Immunology</i> , 2007, 179, 3276-3286. | 0.4 | 46 |
| 93 | Fc μ RI- and Fc γ 3 Receptor-Mediated Production of Reactive Oxygen Species by Mast Cells Is Lipoxygenase- and Cyclooxygenase-Dependent and NADPH Oxidase-Independent. <i>Journal of Immunology</i> , 2007, 179, 7059-7071. | 0.4 | 45 |
| 94 | The Role of c-Kit and Its Ligand, Stem Cell Factor, in Mast Cell Apoptosis. <i>International Archives of Allergy and Immunology</i> , 1995, 107, 136-138. | 0.9 | 43 |
| 95 | A Truncated Splice-Variant of the Fc μ RI β 2 Receptor Subunit Is Critical for Microtubule Formation and Degranulation in Mast Cells. <i>Immunity</i> , 2013, 38, 906-917. | 6.6 | 43 |
| 96 | Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 1155-1161. | 1.5 | 42 |
| 97 | Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. <i>Haematologica</i> , 2008, 93, 49-56. | 1.7 | 42 |
| 98 | Amplification mechanisms for the enhancement of antigen-mediated mast cell activation. <i>Immunologic Research</i> , 2009, 43, 15-24. | 1.3 | 42 |
| 99 | Mast cell ontogeny and apoptosis. <i>Experimental Dermatology</i> , 1995, 4, 227-230. | 1.4 | 41 |
| 100 | High-resolution tracking of cell division demonstrates differential effects of TH1 and TH2 cytokines on SCF-dependent human mast cell production in vitro: correlation with apoptosis and Kit expression. <i>Blood</i> , 2005, 105, 592-599. | 0.6 | 41 |
| 101 | Concurrent Inhibition of Kit- and Fc μ RI-Mediated Signaling: Coordinated Suppression of Mast Cell Activation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 128-138. | 1.3 | 40 |
| 102 | Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 178-187.e1. | 1.5 | 38 |
| 103 | Mastocytosis-derived extracellular vesicles deliver miR-23a and miR-30a into pre-osteoblasts and prevent osteoblastogenesis and bone formation. <i>Nature Communications</i> , 2021, 12, 2527. | 5.8 | 38 |
| 104 | Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1010-1017.e10. | 1.5 | 38 |
| 105 | Targeting Kit Activation: A Potential Therapeutic Approach in the Treatment of Allergic Inflammation. <i>Inflammation and Allergy: Drug Targets</i> , 2007, 6, 57-62. | 1.8 | 36 |
| 106 | Regression of Urticaria Pigmentosa in Adult Patients With Systemic Mastocytosis. <i>Archives of Dermatology</i> , 2002, 138, 785-90. | 1.7 | 35 |
| 107 | Mast cells, which interact with <i>Escherichia coli</i> , up-regulate genes associated with innate immunity and become less responsive to Fc μ RI-mediated activation. <i>Journal of Leukocyte Biology</i> , 2006, 79, 339-350. | 1.5 | 35 |
| 108 | Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1999-2012.e6. | 2.0 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Detection of <i>KIT</i> D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease. <i>British Journal of Haematology</i> , 2018, 183, 775-782. | 1.2 | 34 |
| 110 | Mastocytosis-derived extracellular vesicles exhibit a mast cell signature, transfer KIT to stellate cells, and promote their activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10692-E10701. | 3.3 | 34 |
| 111 | Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3918-3928. | 2.0 | 33 |
| 112 | Emerging mechanisms contributing to mast cell-mediated pathophysiology with therapeutic implications. , 2021, 220, 107718. | | 32 |
| 113 | Radiotherapy of Refractory Bone Pain Due to Systemic Mast Cell Disease. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994, 17, 328-330. | 0.6 | 31 |
| 114 | Distinct transcriptome profiles differentiate nonsteroidal anti-inflammatory drug-dependent from nonsteroidal anti-inflammatory drug-independent food-induced anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 137-146. | 1.5 | 31 |
| 115 | COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2139-2144. | 2.0 | 31 |
| 116 | Clinical relevance of inherited genetic differences in human tryptases. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 638-647. | 0.5 | 30 |
| 117 | An optimized protocol for the generation and functional analysis of human mast cells from CD34 + enriched cell populations. <i>Journal of Immunological Methods</i> , 2017, 448, 105-111. | 0.6 | 28 |
| 118 | Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production. <i>Haematologica</i> , 2020, 105, 124-135. | 1.7 | 26 |
| 119 | A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1004-1010.e2. | 1.5 | 25 |
| 120 | Genetically modified crops and allergenicity. <i>Nature Immunology</i> , 2005, 6, 857-860. | 7.0 | 24 |
| 121 | IgE-FcγRI Interactions Determine HIV Coreceptor Usage and Susceptibility to Infection during Ontogeny of Mast Cells. <i>Journal of Immunology</i> , 2009, 182, 6401-6409. | 0.4 | 24 |
| 122 | Demonstration and characterization of a transient arthritis in rats following sensitization of synovial mast cells with antigen-specific ige and parenteral challenge with specific antigen. <i>Arthritis and Rheumatism</i> , 1988, 31, 1063-1067. | 6.7 | 23 |
| 123 | Interferon-γ enhances both the anti-bacterial and the pro-inflammatory response of human mast cells to <i>Staphylococcus aureus</i> . <i>Immunology</i> , 2015, 146, 470-485. | 2.0 | 23 |
| 124 | Description and Characterization of a Novel Human Mast Cell Line for Scientific Study. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5520. | 1.8 | 23 |
| 125 | Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 300-306. | 1.5 | 23 |
| 126 | Critical Signaling Events in the Mechanoactivation of Human Mast Cells through p.C492Y-ADGRE2. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2210-2220.e5. | 0.3 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Cytogenetic abnormalities and their lack of relationship to the Asp816Val c-kit mutation in the pathogenesis of mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 523-524. | 1.5 | 21 |
| 128 | Thrombopoietin alone or in the presence of stem cell factor supports the growth of KIT(CD117) ^{low} /MPL(CD110) ⁺ human mast cells from hematopoietic progenitor cells. <i>Experimental Hematology</i> , 2005, 33, 413-421. | 0.2 | 21 |
| 129 | Glycogen Synthase Kinase 3 ^β Activation Is a Prerequisite Signal for Cytokine Production and Chemotaxis in Human Mast Cells. <i>Journal of Immunology</i> , 2010, 184, 564-572. | 0.4 | 21 |
| 130 | Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 411. | 1.8 | 21 |
| 131 | Secretion of Interleukin-1 Receptor Antagonist from Human Mast Cells after Immunoglobulin E ^ε -Mediated Activation and after Segmental Antigen Challenge. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001, 25, 685-691. | 1.4 | 20 |
| 132 | Mast Cell Migratory Response to Interleukin-8 Is Mediated Through Interaction With Chemokine Receptor CXCR2/Interleukin-8RB. <i>Blood</i> , 1999, 93, 2791-2797. | 0.6 | 20 |
| 133 | Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1953-1963. | 2.0 | 20 |
| 134 | Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1314-1316. | 2.0 | 19 |
| 135 | Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1855-1865. | 1.5 | 19 |
| 136 | Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. <i>Haematologica</i> , 2018, 103, 1760-1771. | 1.7 | 18 |
| 137 | Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1866-1874. | 1.5 | 18 |
| 138 | KIT GNNK splice variants: Expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells. <i>Experimental Hematology</i> , 2013, 41, 870-881.e2. | 0.2 | 17 |
| 139 | Incorporating Tryptase Genotyping Into the Workup and Diagnosis of Mast Cell Diseases and Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1964-1973. | 2.0 | 17 |
| 140 | Expression of MRGPRX2 in skin mast cells of patients with maculopapular cutaneous mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3841-3843.e1. | 2.0 | 16 |
| 141 | Regulation of normal and neoplastic human mast cell development in mastocytosis. <i>Transactions of the American Clinical and Climatological Association</i> , 2005, 116, 185-203; discussion 203-4. | 0.9 | 15 |
| 142 | Targeting Mast Cells with Biologics. <i>Immunology and Allergy Clinics of North America</i> , 2020, 40, 667-685. | 0.7 | 14 |
| 143 | Growth of Human Mast Cells from Bone Marrow and Peripheral Blood-Derived CD34 ⁺ Pluripotent Hematopoietic Cells. <i>Methods in Molecular Biology</i> , 2015, 1220, 155-162. | 0.4 | 14 |
| 144 | Glycogen Synthase Kinase-3 ^β Is a Prosurvival Signal for the Maintenance of Human Mast Cell Homeostasis. <i>Journal of Immunology</i> , 2011, 187, 5587-5595. | 0.4 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | S1P4 Regulates Passive Systemic Anaphylaxis in Mice but Is Dispensable for Canonical IgE-Mediated Responses in Mast Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1279. | 1.8 | 12 |
| 146 | Impulse oscillometry identifies peripheral airway dysfunction in children with adenosine deaminase deficiency. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 159. | 1.2 | 10 |
| 147 | Regulation of Reactive Oxygen Species and the Antioxidant Protein DJ-1 in Mastocytosis. <i>PLoS ONE</i> , 2016, 11, e0162831. | 1.1 | 9 |
| 148 | Chromogranin A is not a biomarker of mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 687-689.e4. | 2.0 | 8 |
| 149 | Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT. <i>Frontiers in Immunology</i> , 2018, 9, 631. | 2.2 | 8 |
| 150 | Seafood toxins. <i>Clinical Reviews in Allergy</i> , 1993, 11, 241-60. | 1.0 | 8 |
| 151 | Interaction of DJ-1 with Lyn is essential for IgE-mediated stimulation of human mast cells. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 195-206.e8. | 1.5 | 7 |
| 152 | Assessment of Osteoporosis and Fracture Risk in Mastocytosis within a North American Cohort. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4459-4467.e10. | 2.0 | 6 |
| 153 | A personal perspective on mentoring. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 548-549. | 1.5 | 5 |
| 154 | Skewed Lymphocyte Subpopulations and Associated Phenotypes in Patients with Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 292-301.e2. | 2.0 | 5 |
| 155 | Inhibition of Allergic Reactivity through Targeting Fc μ RI-Bound IgE with Humanized Low-Affinity Antibodies. <i>Journal of Immunology</i> , 2019, 203, 2777-2790. | 0.4 | 4 |
| 156 | Elevation in histamine and tryptase following exercise in patients with mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1310-1313.e2. | 2.0 | 3 |
| 157 | Aldh2 Attenuates Stem Cell Factor/Kit-Dependent Signaling and Activation in Mast Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6216. | 1.8 | 3 |
| 158 | Mast cells, basophils, and mastocytosis. , 2013, , 284-297. | | 3 |
| 159 | Decoding the intricacies of the mast cell compartment. <i>British Journal of Haematology</i> , 2021, , . | 1.2 | 2 |
| 160 | Acute increases in total serum tryptase unassociated with hemodynamic instability in diffuse cutaneous mastocytosis. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 249-252. | 0.5 | 2 |
| 161 | Providing the TORC for cell cycle progression in neoplastic mast cells. <i>Cell Cycle</i> , 2012, 11, 210-211. | 1.3 | 1 |
| 162 | Maculopapular Cutaneous Mastocytosis in a Diverse Population. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2845-2847. | 2.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Reply. Journal of Allergy and Clinical Immunology, 2019, 143, 451-452. | 1.5 | 1 |
| 164 | A study of microbial translocation markers in mastocytosis. Clinical and Experimental Allergy, 2021, 51, 369-372. | 1.4 | 1 |
| 165 | Demonstration and implications of IL-3 upregulation of CD25 expression on human mast cells. Journal of Allergy and Clinical Immunology, 2021, , . | 1.5 | 1 |
| 166 | Systemic mastocytosis. , 2012, , 369-378. | | 0 |
| 167 | Mast Cell Precursors and Signaling Pathways. , 2010, , 283-295. | | 0 |
| 168 | History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis. , 2020, , 287-299. | | 0 |
| 169 | Remission of indolent systemic mastocytosis in the absence of targeted therapy. Journal of Allergy and Clinical Immunology: in Practice, 2022, , . | 2.0 | 0 |